Selected research
Market Structure
Global Drugs for Sexual Dysfunction Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Drugs for Sexual Dysfunction market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Drugs for Sexual Dysfunction include Boston Scientific Corporation, CSBio, Dong-A ST, General Factory, Hims, Lilly ICOS LLC, Lupin, Meda Pharmaceuticals and Menarini Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Drugs for Sexual Dysfunction market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Drugs for Sexual Dysfunction and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Drugs for Sexual Dysfunction sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Sexual Dysfunction market size, projected growth trends, production technologies, key applications, and end-use industries.
Drugs for Sexual Dysfunction Segment by Company
Boston Scientific Corporation
CSBio
Dong-A ST
General Factory
Hims
Lilly ICOS LLC
Lupin
Meda Pharmaceuticals
Menarini Group
Metuchen Pharma
SK Chemicals.
Vivus, Inc.
Bayer AG
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Pfizer Inc
Lilly
Sanofi
Teva Pharmaceutical Industries Ltd.
Drugs for Sexual Dysfunction Segment by Type
Vardenafil (Levitra, Staxyn)
Tadalafil (Cialis)
Udenafil (Zydena)
Sildenafil (Viagra)
Others
Drugs for Sexual Dysfunction Segment by Application
Retail Pharmacies
Online Pharmacies
Hospitals
Clinics
Drugs for Sexual Dysfunction Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Sexual Dysfunction market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Sexual Dysfunction and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Sexual Dysfunction.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Drugs for Sexual Dysfunction market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Sexual Dysfunction manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Sexual Dysfunction in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Drugs for Sexual Dysfunction in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Vardenafil (Levitra, Staxyn)
- Tadalafil (Cialis)
- Udenafil (Zydena)
- Sildenafil (Viagra)
- Others
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospitals
- Clinics
Companies covered
- Boston Scientific Corporation
- CSBio
- Dong-A ST
- General Factory
- Hims
- Lilly ICOS LLC
- Lupin
- Meda Pharmaceuticals
- Menarini Group
- Metuchen Pharma
- SK Chemicals.
- Vivus, Inc.
- Bayer AG
- Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
- Pfizer Inc
- Lilly
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Drugs for Sexual Dysfunction Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Drugs for Sexual Dysfunction Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Drugs for Sexual Dysfunction Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Drugs for Sexual Dysfunction Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Drugs for Sexual Dysfunction Market Dynamics
- 2.1 Drugs for Sexual Dysfunction Industry Trends
- 2.2 Drugs for Sexual Dysfunction Industry Drivers
- 2.3 Drugs for Sexual Dysfunction Industry Opportunities and Challenges
- 2.4 Drugs for Sexual Dysfunction Industry Restraints
3 Drugs for Sexual Dysfunction Market by Manufacturers
- 3.1 Global Drugs for Sexual Dysfunction Revenue by Manufacturers (2021-2026)
- 3.2 Global Drugs for Sexual Dysfunction Sales by Manufacturers (2021-2026)
- 3.3 Global Drugs for Sexual Dysfunction Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Drugs for Sexual Dysfunction Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Drugs for Sexual Dysfunction Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Drugs for Sexual Dysfunction Manufacturers, Product Type & Application
- 3.7 Global Drugs for Sexual Dysfunction Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Drugs for Sexual Dysfunction Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Drugs for Sexual Dysfunction Players Market Share by Revenue in 2025
- 3.8.3 2025 Drugs for Sexual Dysfunction Tier 1, Tier 2, and Tier 3
4 Drugs for Sexual Dysfunction Market by Type
- 4.1 Drugs for Sexual Dysfunction Type Introduction
- 4.1.1 Vardenafil (Levitra, Staxyn)
- 4.1.2 Tadalafil (Cialis)
- 4.1.3 Udenafil (Zydena)
- 4.1.4 Sildenafil (Viagra)
- 4.1.5 Others
- 4.2 Global Drugs for Sexual Dysfunction Sales by Type
- 4.2.1 Global Drugs for Sexual Dysfunction Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Drugs for Sexual Dysfunction Sales by Type (2021-2032)
- 4.2.3 Global Drugs for Sexual Dysfunction Sales Market Share by Type (2021-2032)
- 4.3 Global Drugs for Sexual Dysfunction Revenue by Type
- 4.3.1 Global Drugs for Sexual Dysfunction Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Drugs for Sexual Dysfunction Revenue by Type (2021-2032)
- 4.3.3 Global Drugs for Sexual Dysfunction Revenue Market Share by Type (2021-2032)
5 Drugs for Sexual Dysfunction Market by Application
- 5.1 Drugs for Sexual Dysfunction Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Online Pharmacies
- 5.1.3 Hospitals
- 5.1.4 Clinics
- 5.2 Global Drugs for Sexual Dysfunction Sales by Application
- 5.2.1 Global Drugs for Sexual Dysfunction Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Drugs for Sexual Dysfunction Sales by Application (2021-2032)
- 5.2.3 Global Drugs for Sexual Dysfunction Sales Market Share by Application (2021-2032)
- 5.3 Global Drugs for Sexual Dysfunction Revenue by Application
- 5.3.1 Global Drugs for Sexual Dysfunction Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Drugs for Sexual Dysfunction Revenue by Application (2021-2032)
- 5.3.3 Global Drugs for Sexual Dysfunction Revenue Market Share by Application (2021-2032)
6 Global Drugs for Sexual Dysfunction Sales by Region
- 6.1 Global Drugs for Sexual Dysfunction Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Drugs for Sexual Dysfunction Sales by Region (2021-2032)
- 6.2.1 Global Drugs for Sexual Dysfunction Sales by Region (2021-2026)
- 6.2.2 Global Drugs for Sexual Dysfunction Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Drugs for Sexual Dysfunction Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Drugs for Sexual Dysfunction Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Drugs for Sexual Dysfunction Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Drugs for Sexual Dysfunction Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Drugs for Sexual Dysfunction Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Drugs for Sexual Dysfunction Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Drugs for Sexual Dysfunction Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Drugs for Sexual Dysfunction Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Drugs for Sexual Dysfunction Revenue by Region
- 7.1 Global Drugs for Sexual Dysfunction Revenue by Region
- 7.1.1 Global Drugs for Sexual Dysfunction Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Drugs for Sexual Dysfunction Revenue by Region (2021-2026)
- 7.1.3 Global Drugs for Sexual Dysfunction Revenue by Region (2027-2032)
- 7.1.4 Global Drugs for Sexual Dysfunction Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Drugs for Sexual Dysfunction Revenue (2021-2032)
- 7.2.2 North America Drugs for Sexual Dysfunction Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Drugs for Sexual Dysfunction Revenue (2021-2032)
- 7.3.2 Europe Drugs for Sexual Dysfunction Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Drugs for Sexual Dysfunction Revenue (2021-2032)
- 7.4.2 Asia-Pacific Drugs for Sexual Dysfunction Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Drugs for Sexual Dysfunction Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Drugs for Sexual Dysfunction Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Boston Scientific Corporation
- 8.1.1 Boston Scientific Corporation Company Information
- 8.1.2 Boston Scientific Corporation Business Overview
- 8.1.3 Boston Scientific Corporation Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Boston Scientific Corporation Drugs for Sexual Dysfunction Product Portfolio
- 8.1.5 Boston Scientific Corporation Recent Developments
- 8.2 CSBio
- 8.2.1 CSBio Company Information
- 8.2.2 CSBio Business Overview
- 8.2.3 CSBio Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 CSBio Drugs for Sexual Dysfunction Product Portfolio
- 8.2.5 CSBio Recent Developments
- 8.3 Dong-A ST
- 8.3.1 Dong-A ST Company Information
- 8.3.2 Dong-A ST Business Overview
- 8.3.3 Dong-A ST Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Dong-A ST Drugs for Sexual Dysfunction Product Portfolio
- 8.3.5 Dong-A ST Recent Developments
- 8.4 General Factory
- 8.4.1 General Factory Company Information
- 8.4.2 General Factory Business Overview
- 8.4.3 General Factory Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 General Factory Drugs for Sexual Dysfunction Product Portfolio
- 8.4.5 General Factory Recent Developments
- 8.5 Hims
- 8.5.1 Hims Company Information
- 8.5.2 Hims Business Overview
- 8.5.3 Hims Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Hims Drugs for Sexual Dysfunction Product Portfolio
- 8.5.5 Hims Recent Developments
- 8.6 Lilly ICOS LLC
- 8.6.1 Lilly ICOS LLC Company Information
- 8.6.2 Lilly ICOS LLC Business Overview
- 8.6.3 Lilly ICOS LLC Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Lilly ICOS LLC Drugs for Sexual Dysfunction Product Portfolio
- 8.6.5 Lilly ICOS LLC Recent Developments
- 8.7 Lupin
- 8.7.1 Lupin Company Information
- 8.7.2 Lupin Business Overview
- 8.7.3 Lupin Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Lupin Drugs for Sexual Dysfunction Product Portfolio
- 8.7.5 Lupin Recent Developments
- 8.8 Meda Pharmaceuticals
- 8.8.1 Meda Pharmaceuticals Company Information
- 8.8.2 Meda Pharmaceuticals Business Overview
- 8.8.3 Meda Pharmaceuticals Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Meda Pharmaceuticals Drugs for Sexual Dysfunction Product Portfolio
- 8.8.5 Meda Pharmaceuticals Recent Developments
- 8.9 Menarini Group
- 8.9.1 Menarini Group Company Information
- 8.9.2 Menarini Group Business Overview
- 8.9.3 Menarini Group Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Menarini Group Drugs for Sexual Dysfunction Product Portfolio
- 8.9.5 Menarini Group Recent Developments
- 8.10 Metuchen Pharma
- 8.10.1 Metuchen Pharma Company Information
- 8.10.2 Metuchen Pharma Business Overview
- 8.10.3 Metuchen Pharma Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Metuchen Pharma Drugs for Sexual Dysfunction Product Portfolio
- 8.10.5 Metuchen Pharma Recent Developments
- 8.11 SK Chemicals.
- 8.11.1 SK Chemicals. Company Information
- 8.11.2 SK Chemicals. Business Overview
- 8.11.3 SK Chemicals. Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 SK Chemicals. Drugs for Sexual Dysfunction Product Portfolio
- 8.11.5 SK Chemicals. Recent Developments
- 8.12 Vivus, Inc.
- 8.12.1 Vivus, Inc. Company Information
- 8.12.2 Vivus, Inc. Business Overview
- 8.12.3 Vivus, Inc. Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Vivus, Inc. Drugs for Sexual Dysfunction Product Portfolio
- 8.12.5 Vivus, Inc. Recent Developments
- 8.13 Bayer AG
- 8.13.1 Bayer AG Company Information
- 8.13.2 Bayer AG Business Overview
- 8.13.3 Bayer AG Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Bayer AG Drugs for Sexual Dysfunction Product Portfolio
- 8.13.5 Bayer AG Recent Developments
- 8.14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
- 8.14.1 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Company Information
- 8.14.2 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Business Overview
- 8.14.3 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Product Portfolio
- 8.14.5 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Recent Developments
- 8.15 Pfizer Inc
- 8.15.1 Pfizer Inc Company Information
- 8.15.2 Pfizer Inc Business Overview
- 8.15.3 Pfizer Inc Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Pfizer Inc Drugs for Sexual Dysfunction Product Portfolio
- 8.15.5 Pfizer Inc Recent Developments
- 8.16 Lilly
- 8.16.1 Lilly Company Information
- 8.16.2 Lilly Business Overview
- 8.16.3 Lilly Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Lilly Drugs for Sexual Dysfunction Product Portfolio
- 8.16.5 Lilly Recent Developments
- 8.17 Sanofi
- 8.17.1 Sanofi Company Information
- 8.17.2 Sanofi Business Overview
- 8.17.3 Sanofi Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Sanofi Drugs for Sexual Dysfunction Product Portfolio
- 8.17.5 Sanofi Recent Developments
- 8.18 Teva Pharmaceutical Industries Ltd.
- 8.18.1 Teva Pharmaceutical Industries Ltd. Company Information
- 8.18.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 8.18.3 Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Product Portfolio
- 8.18.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Drugs for Sexual Dysfunction Value Chain Analysis
- 9.1.1 Drugs for Sexual Dysfunction Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Drugs for Sexual Dysfunction Production Mode & Process
- 9.2 Drugs for Sexual Dysfunction Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Drugs for Sexual Dysfunction Distributors
- 9.2.3 Drugs for Sexual Dysfunction Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst